Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

Inclusion Criteria:

• Able to understand and comply with study procedures and give written informedconsent

• Age ≥18 years

• NAS ≥4 with a score of at least 1 in each component of the NAS (steatosis, lobularinflammation, and ballooning) at Visit 2 liver biopsy, or a historical liver biopsyperformed within 24 weeks of randomization

• Fibrosis stage of 1 or greater and below 4 on NASH CRN (Clinical Research Network)fibrosis staging system at Visit 2 liver biopsy, or a historical liver biopsyperformed within 24 weeks of randomization

• Meet all inclusion criteria outlined in clinical study protocol

Exclusion Criteria:

• Participation in another clinical trial involving an investigational agent within 30days prior to signing the Informed Consent Form (ICF) for this study

• Ongoing or recent consumption of Greater than moderate amounts of alcohol as definedin clinical study protocol

• Evidence of other forms of chronic liver disease as defined in clinical studyprotocol

• Does not meet any other exclusion criteria outlined in clinical study protocol